Goldman Sachs’s Teva Pharmaceuticals TEVA Stock Holding History

Goldman Sachs’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,139,900	Closed	-$66.8M	–	6970
2025 Q4	$66.8M	Buy	2,139,900 +950,000	+80%	+$23.4M	0.01%	1262
2025 Q3	$24M	Buy	1,189,900 +1,050,000	+751%	+$18.4M	﹤0.01%	2084
2025 Q2	$2.34M	Hold	139,900	–	–	﹤0.01%	4050
2025 Q1	$2.15M	Sell	139,900 -337,100	-71%	-$6.02M	﹤0.01%	4101
2024 Q4	$10.5M	Buy	477,000 +357,000	+298%	+$6.49M	﹤0.01%	2760
2024 Q3	$2.16M	Buy	+120,000	New	+$2.1M	﹤0.01%	4092
2024 Q1	–	Sell	-847,400	Closed	-$8.85M	–	5879
2023 Q4	$8.85M	Sell	847,400 -450,000	-35%	-$4.2M	﹤0.01%	2647
2023 Q3	$13.2M	Hold	1,297,400	–	–	﹤0.01%	2154
2023 Q2	$9.77M	Hold	1,297,400	–	–	﹤0.01%	2477
2023 Q1	$11.5M	Sell	1,297,400 -238,500	-16%	-$2.36M	﹤0.01%	2291
2022 Q4	$14M	Hold	1,535,900	–	–	﹤0.01%	2273
2022 Q3	$12.4M	Hold	1,535,900	–	–	﹤0.01%	2314
2022 Q2	$11.6M	Hold	1,535,900	–	–	﹤0.01%	2372
2022 Q1	$14.4M	Hold	1,535,900	–	–	﹤0.01%	2329
2021 Q4	$12.3M	Buy	1,535,900 +1,380,900	+891%	+$12.5M	﹤0.01%	2570
2021 Q3	$1.51M	Buy	+155,000	New	+$1.45M	﹤0.01%	4427
2021 Q1	–	Sell	-100,000	Closed	-$965K	–	6346
2020 Q4	$965K	Hold	100,000	–	–	﹤0.01%	4221
2020 Q3	$901K	Hold	100,000	–	–	﹤0.01%	4154
2020 Q2	$1.23M	Sell	100,000 -1,133,800	-92%	-$12.8M	﹤0.01%	3807
2020 Q1	$11.1M	Sell	1,233,800 -1,264,300	-51%	-$13M	﹤0.01%	2016
2019 Q4	$24.5M	Buy	2,498,100 +871,100	+54%	+$7.78M	0.01%	1695
2019 Q3	$11.2M	Buy	1,627,000 +1,077,000	+196%	+$8.25M	﹤0.01%	2234
2019 Q2	$5.08M	Hold	550,000	–	–	﹤0.01%	2833
2019 Q1	$8.62M	Sell	550,000 -157,700	-22%	-$2.78M	﹤0.01%	2538
2018 Q4	$10.9M	Buy	707,700 +50,400	+8%	+$1.03M	﹤0.01%	2291
2018 Q3	$14.2M	Buy	657,300 +100,000	+18%	+$2.32M	﹤0.01%	2182
2018 Q2	$13.6M	Sell	557,300 -831,200	-60%	-$17M	﹤0.01%	2190
2018 Q1	$23.7M	Buy	1,388,500 +501,200	+56%	+$9.79M	0.01%	1721
2017 Q4	$16.8M	Buy	887,300 +476,300	+116%	+$7.16M	﹤0.01%	2069
2017 Q3	$7.23M	Buy	411,000 +29,200	+8%	+$657K	﹤0.01%	2836
2017 Q2	$12.7M	Buy	381,800 +154,100	+68%	+$4.77M	﹤0.01%	2319
2017 Q1	$7.31M	Sell	227,700 -166,800	-42%	-$5.69M	﹤0.01%	2623
2016 Q4	$14.3M	Buy	394,500 +12,000	+3%	+$479K	﹤0.01%	2204
2016 Q3	$17.6M	Sell	382,500 -226,500	-37%	-$11.8M	0.01%	1989
2016 Q2	$30.6M	Sell	609,000 -653,000	-52%	-$34.8M	0.01%	1473
2016 Q1	$67.5M	Buy	1,262,000 +186,700	+17%	+$11M	0.02%	880
2015 Q4	$70.6M	Buy	1,075,300 +859,400	+398%	+$53.1M	0.02%	881
2015 Q3	$12.2M	Sell	215,900 -313,500	-59%	-$20.3M	﹤0.01%	2102
2015 Q2	$31.3M	Buy	529,400 +160,300	+43%	+$9.89M	0.01%	1470
2015 Q1	$23M	Sell	369,100 -55,400	-13%	-$3.22M	0.01%	1654
2014 Q4	$24.4M	Buy	424,500 +73,900	+21%	+$4.12M	0.01%	1689
2014 Q3	$18.8M	Buy	350,600 +47,900	+16%	+$2.54M	0.01%	1823
2014 Q2	$15.9M	Sell	302,700 -226,200	-43%	-$11.6M	0.01%	1982
2014 Q1	$27.9M	Sell	528,900 -1,466,000	-73%	-$67.8M	0.01%	1496
2013 Q4	$80M	Buy	1,994,900 +627,200	+46%	+$24.7M	0.03%	743
2013 Q3	$51.7M	Buy	1,367,700 +940,000	+220%	+$36.7M	0.02%	933
2013 Q2	$16.8M	Buy	+427,700	New	+$16.7M	0.01%	1663

Other funds holding TEVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs's TEVA Position: Q1 2026 in Review

Goldman Sachs reduced its Teva Pharmaceuticals (TEVA) stake by 18% in Q1 2026, selling an estimated $33.8M and leaving 4,826,245 shares worth $145M. The position accounts for 0.02% of the portfolio, ranked #835.

Goldman Sachs first reported a position in TEVA in Q2 2013 and has held it in 52 quarters since. The position peaked at $328M in Q4 2015. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

Goldman Sachs held 4,826,245 shares of Teva Pharmaceuticals worth $145M as of Q1 2026.
Goldman Sachs sold 1,051,822 Teva Pharmaceuticals shares in Q1 2026, an estimated $33.8M.
Teva Pharmaceuticals made up 0.02% of Goldman Sachs's portfolio in Q1 2026, its #835 holding.
Goldman Sachs first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
Goldman Sachs's Teva Pharmaceuticals position peaked at $328M in Q4 2015.
650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.